NT5E and acute lymphoblastic leukemia: Specifically, CD73 is upregulated in B cell precursors of ALL patients and its expression is not down-modulated upon treatment thus making it a reliable marker to identify residual ALL cells resistant to therapies and potentially responsible for future relapses (146, 147).